SpaceX shares rise as Morgan Stanley reiterates $300 target

SpaceX shares rose 8% Monday morning to $167.71 after Morgan Stanley reiterated its overweight rating and $300 price target. The bank said the stock remains undervalued on a growth-adjusted basis, describing it as “cheap and getting cheaper.”

Analysis

The key signal is not the reiterated rating; it is how much of the repricing is now being anchored to a growth-adjusted valuation narrative. That can support further multiple expansion in the near term, but it is fragile: if expected growth slips or discount rates rise, the same framework can compress the multiple quickly. The broker’s target is not independent evidence of operating upside, and the article provides no valuation inputs, forecasts, or business metrics with which to test it.

Over days, the sharp move raises the risk of chasing a note-driven gap. Over 1–3 months, look for company guidance and measurable operating or financial progress to validate the growth assumptions; over 6–18 months, execution and capital requirements matter more than analyst framing. A broader risk-off move in long-duration growth assets would be a plausible reversal catalyst. There is not enough information here to establish a relative-value trade against competitors or a thesis on Morgan Stanley.

Key Decisions for Investors

• Do not chase the opening strength solely on the reiterated rating and target. For an existing position, consider trimming into further note-driven strength rather than treating the target as a catalyst-backed valuation floor.
• Keep SPCX on a conditional long watchlist: consider staged exposure only after a pullback or after company disclosures corroborate the growth assumptions. Verify valuation methodology, operating KPIs, cash generation, and any funding needs first.
• Falsification / risk triggers: company guidance or operating indicators that weaken the expected growth path, a material increase in capital requirements, or a sustained retreat in long-duration growth valuations. Reassess if these emerge; the article supplies no defensible price level for a stop.
• No trade in MS on this item: the cited view is its research stance, not evidence of a change in the bank’s earnings outlook.